Details of the Drug

General Information of Drug (ID: DM5SXUV)

• Drug Name: Repaglinide
• Synonyms: Actulin; GlucoNorm; NovoNorm; Prandin; Repaglinida; Repaglinidum; Glaxo Wellcome brand of replaginide; Novo Nordisk brand of repaglinide; Repaglinide [USAN]; Novo Nordisk brand 2 of repaglinide; AG-EE 388; AG-EE 388 ZW; AG-EE 623 ZW; AGEE-623ZW; GlucoNorm (TN); NN-623; NovoNorm (TN); Prandin (TN); Repa-glinide; Repaglinida [INN-Spanish]; Repaglinidum [INN-Latin]; SMP-508; AG-EE-388; AG-EE-623 ZW; Prandin, GlucoNorm, NovoNorm, Repaglinide; Repaglinide (JAN/USP/INN); Repaglinide, (+-)-isomer; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 111GE012; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[1]

• Therapeutic Class: Hypoglycemic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 452.6
  Logarithm of the Partition Coefficient (xlogp); 5.2
  Rotatable Bond Count (rotbonds); 10
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
  Bioavailability: 56% of drug becomes completely available to its intended biological destination(s) [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 7.8 mL/min/kg [4]
  Elimination: 1.5% of drug is excreted from urine in the unchanged form [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 1 hours [4]
  Metabolism: The drug is metabolized via oxidation and dealkylation by cytochrome P450 3A4 and 2C9 to form the major dicarboxylic acid derivative (M2) []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.473 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.015% [4]
  Vd: The volume of distribution (Vd) of drug is 31 L []
• Chemical Identifiers:
  Formula: C27H36N2O4
  IUPAC Name: 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
  Canonical SMILES: CCOC1=C(C=CC(=C1)CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O
  InChI: InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1
  InChIKey: FAEKWTJYAYMJKF-QHCPKHFHSA-N
• Cross-matching ID:
  PubChem CID: 65981
  ChEBI ID: CHEBI:8805
  CAS Number: 135062-02-1
  DrugBank ID: DB00912
  TTD ID: D0N5YA
  VARIDT ID: DR00446
  INTEDE ID: DR1404
  ACDINA ID: D00587

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ATP-binding cassette transporter C8 (ABCC8)	TTP835K	ABCC8_HUMAN	Blocker	[6]
ATP-binding cassette transporter C9 (ABCC9)	TTEF5MJ	ABCC9_HUMAN	Blocker	[6]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[7]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[9]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[8]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[10]
HLA class I histocompatibility antigen, alpha chain F (HLA-F)	OT76CM19	HLAF_HUMAN	Gene/Protein Processing	[11]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Gene/Protein Processing	[12]
Major histocompatibility complex class I-related gene protein (MR1)	OTZU3XX7	HMR1_HUMAN	Gene/Protein Processing	[11]
Solute carrier family 15 member 1 (SLC15A1)	OT1P16B5	S15A1_HUMAN	Gene/Protein Processing	[13]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1)	OTNEN8QK	SO1B1_HUMAN	Regulation of Drug Effects	[14]

Molecular Expression Atlas of This Drug

• The Studied Disease: Diabetic complication
• ICD Disease Classification: 5A2Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
ATP-binding cassette transporter C9 (ABCC9)	DTT	ABCC9	6.51E-01	0.02	0.06
ATP-binding cassette transporter C9 (ABCC9)	DTT	ABCC9	8.46E-01	0.02	0.22
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DTP	OATP1B1	2.41E-01	-2.63E-02	-8.50E-02
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DTP	OATP1B1	5.54E-01	-1.65E-02	-1.24E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	8.29E-01	-5.44E-03	-2.25E-02
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	4.23E-03	9.31E-02	4.30E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	2.41E-01	3.17E-02	2.29E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	5.67E-01	5.11E-02	1.35E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	2.13E-01	4.03E-02	2.50E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	8.21E-02	8.17E-02	4.35E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Repaglinide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Pioglitazone	DMKJ485	Moderate	Increased metabolism of Repaglinide caused by Pioglitazone mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[15]

Coadministration of a Drug Treating the Disease Different from Repaglinide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Repaglinide caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[16]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Repaglinide caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[16]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Repaglinide caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[16]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Repaglinide caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[16]
Oxymetholone	DMFXUT8	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Oxymetholone.	Aplastic anaemia [3A70]	[17]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Repaglinide caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[16]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Repaglinide caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[18]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Repaglinide caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[16]
Sulfamethoxazole	DMB08GE	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[17]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Repaglinide caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[16]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Repaglinide caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[16]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Repaglinide due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[19]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Repaglinide caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[16]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Repaglinide caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[16]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Repaglinide caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[16]
Fluoxymesterone	DMUHCF1	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Fluoxymesterone.	Breast cancer [2C60-2C6Y]	[17]
Fenofibric acid	DMGO2MC	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Fenofibric acid.	Cardiovascular disease [BA00-BE2Z]	[17]
Ketoprofen	DMRKXPT	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Ketoprofen.	Chronic pain [MG30]	[17]
Ardeparin	DMYRX8B	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Ardeparin.	Coronary thrombosis [BA43]	[17]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Repaglinide caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[20]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Repaglinide caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[16]
Sertraline	DM0FB1J	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Sertraline.	Depression [6A70-6A7Z]	[17]
Vilazodone	DM4LECQ	Moderate	Decreased metabolism of Repaglinide caused by Vilazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[16]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Repaglinide caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[16]
Selegiline	DM6034S	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Selegiline.	Depression [6A70-6A7Z]	[17]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Vortioxetine.	Depression [6A70-6A7Z]	[17]
Isocarboxazid	DMAF1NB	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Isocarboxazid.	Depression [6A70-6A7Z]	[17]
Escitalopram	DMFK9HG	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Escitalopram.	Depression [6A70-6A7Z]	[17]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Repaglinide caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Repaglinide caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Repaglinide caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Repaglinide caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Repaglinide caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Tazemetostat	DMWP1BH	Moderate	Decreased metabolism of Repaglinide caused by Tazemetostat mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[16]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Repaglinide caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[16]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Repaglinide caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[16]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Repaglinide caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[16]
Sunitinib	DMCBJSR	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[17]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Repaglinide caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[16]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Repaglinide caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[16]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Repaglinide caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[16]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Repaglinide caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[16]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Repaglinide caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[16]
Fosamprenavir	DM4W9B3	Moderate	Increased metabolism of Repaglinide caused by Fosamprenavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Repaglinide due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Repaglinide caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Saquinavir	DMG814N	Moderate	Increased metabolism of Repaglinide caused by Saquinavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Repaglinide caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Darunavir	DMN3GCH	Moderate	Antagonize the effect of Repaglinide when combined with Darunavir.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Atazanavir	DMSYRBX	Moderate	Increased metabolism of Repaglinide caused by Atazanavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Bempedoic acid	DM1CI9R	Moderate	Decreased clearance of Repaglinide due to the transporter inhibition by Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[23]
Gemfibrozil	DMD8Q3J	Major	Decreased clearance of Repaglinide due to the transporter inhibition by Gemfibrozil.	Hyper-lipoproteinaemia [5C80]	[16]
Fenofibrate	DMFKXDY	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Fenofibrate.	Hyper-lipoproteinaemia [5C80]	[17]
Teriflunomide	DMQ2FKJ	Moderate	Decreased metabolism of Repaglinide caused by Teriflunomide mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[24]
Captopril	DM458UM	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Captopril.	Hypertension [BA00-BA04]	[17]
Probenecid	DMMFWOJ	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Probenecid.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[17]
Balsalazide	DM7I1T9	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Balsalazide.	Indeterminate colitis [DD72]	[17]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[25]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Repaglinide caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[16]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Repaglinide caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[16]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Repaglinide caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[16]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Repaglinide caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[16]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Repaglinide caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[16]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Hydroxychloroquine.	Malaria [1F40-1F45]	[17]
Sulphadoxine	DMZI2UF	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Sulphadoxine.	Malaria [1F40-1F45]	[17]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Repaglinide caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[16]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Repaglinide caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[16]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Repaglinide caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[16]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Repaglinide caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[19]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Repaglinide caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[26]
Mecasermin	DM1O3BY	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Mecasermin.	Multiple structural anomalies syndrome [LD2F]	[17]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Repaglinide caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[16]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Repaglinide caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[16]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Repaglinide caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[18]
Olaparib	DM8QB1D	Moderate	Decreased clearance of Repaglinide due to the transporter inhibition by Olaparib.	Ovarian cancer [2C73]	[19]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Repaglinide caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[16]
Aspirin	DM672AH	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Aspirin.	Pain [MG30-MG3Z]	[25]
Ibuprofen	DM8VCBE	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Ibuprofen.	Pain [MG30-MG3Z]	[17]
Safinamide	DM0YWJC	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Safinamide.	Parkinsonism [8A00]	[17]
Rasagiline	DM3WKQ4	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Rasagiline.	Parkinsonism [8A00]	[17]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Repaglinide caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[27]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Repaglinide caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[28]
Choline salicylate	DM8P137	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[17]
Bromfenac	DMKB79O	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Bromfenac.	Postoperative inflammation [1A00-CA43]	[17]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Repaglinide caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[16]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Repaglinide caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[16]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Repaglinide caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[16]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Repaglinide due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[29]
Bicalutamide	DMZMSPF	Moderate	Decreased metabolism of Repaglinide caused by Bicalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[16]
Salsalate	DM13P4C	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Salsalate.	Rheumatoid arthritis [FA20]	[17]
Oxaprozin	DM9UB0P	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Oxaprozin.	Rheumatoid arthritis [FA20]	[17]
Salicyclic acid	DM2F8XZ	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[25]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Repaglinide caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[16]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Repaglinide caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[29]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Repaglinide caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[19]
Ifosfamide	DMCT3I8	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[17]
Armodafinil	DMGB035	Moderate	Increased metabolism of Repaglinide caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[16]
LEE011	DMMX75K	Moderate	Decreased metabolism of Repaglinide caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[16]
Methyltestosterone	DMWLFGO	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Methyltestosterone.	Solid tumour/cancer [2A00-2F9Z]	[17]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Repaglinide caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[29]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Repaglinide caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[30]
Eltrombopag	DMOGFIX	Moderate	Decreased clearance of Repaglinide due to the transporter inhibition by Eltrombopag.	Thrombocytopenia [3B64]	[31]
Pramlintide	DM0EZ9Q	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Pramlintide.	Type-1/2 diabete [5A10-5A11]	[17]
Olsalazine	DMZW9HA	Moderate	Increased risk of hypoglycemia by the combination of Repaglinide and Olsalazine.	Ulcerative colitis [DD71]	[17]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Repaglinide caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[16]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Repaglinide caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[16]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 1	E00263	19700	Colorant
Meglumine	E00181	8567	Buffering agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Calcium hydrogenphosphate	E00294	24441	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Magnesium stearate	E00208	11177	lubricant
Poloxamer 188	E00645	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Poloxamer 407	E00646	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Repaglinide 0.5 mg tablet	0.5 mg	Oral Tablet	Oral
Repaglinide 1 mg tablet	1 mg	Oral Tablet	Oral
Repaglinide 2 mg tablet	2 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6841).
• [2] BDDCS applied to over 900 drugs
• [3] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3.
• [7] Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. Clin Pharmacol Ther. 2018 Nov;104(5):900-915.
• [8] Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
• [9] Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br J Clin Pharmacol. 2010 Dec;70(6):870-80.
• [10] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [11] Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
• [12] Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays. Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):241-9.
• [13] In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharm Res. 2005 Apr;22(4):512-7. doi: 10.1007/s11095-005-2505-y. Epub 2005 Apr 7.
• [14] Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 Jun;77(6):468-78. doi: 10.1016/j.clpt.2005.01.018.
• [15] Product Information. Actos (pioglitazone) Takeda Pharmaceuticals America, Lincolnshire, IL.
• [16] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
• [17] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
• [18] Hatorp V, Hansen KT, Thomsen MS "Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide." J Clin Pharmacol 43 (2003): 649-60. [PMID: 12817528]
• [19] Cerner Multum, Inc. "Australian Product Information.".
• [20] Cerner Multum, Inc. "Canadian Product Information.".
• [21] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4. [PMID: 9291911]
• [22] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [23] Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
• [24] Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
• [25] Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
• [26] Canadian Pharmacists Association.
• [27] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [28] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [29] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [30] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [31] Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9. [PMID: 21434975]